TECH – Doximity, a leading digital platform serving U.S. healthcare professionals, has acquired Montreal-based medical AI startup Pathway Medical Inc. for $63 million. Pathway specializes in providing clinicians with AI-driven, evidence-based clinical reference tools, reinforcing Doximity’s strategy of expanding its AI capabilities and resources for medical practitioners.
Founded with a mission to democratize high-quality medical knowledge, Pathway leverages machine learning to help clinicians quickly access relevant clinical guidelines and research, aiming to speed up evidence-based decision-making in practice. The platform already supports healthcare professionals across more than 180 countries and 30+ specialties.
By integrating Pathway’s robust AI reference platform, Doximity is poised to deepen its existing offerings—such as secure messaging, telehealth services, scheduling tools, and the popular Doximity newsfeed—with advanced decision support features. Pathway’s technology can help fill gaps in clinician workflows by providing instant, accurate guidance through an ever-growing body of medical knowledge.
Read More: Meet Xueba 01: The First Robot to Pursue a PhD in Theatre
This move also underscores a broader trend of consolidation in clinical AI, where established digital health companies bolster their product suites through strategic acquisitions. For Doximity, which has seen strong financial performance in recent years—as showcased by rising revenues and active clinician engagement across its suite—this acquisition sharpens its competitive edge.
However, it’s worth noting that both Doximity and Pathway are currently involved in legal controversy. In a federal lawsuit filed by OpenEvidence, both companies stand accused of engaging in “prompt injection” attacks—attempts to extract proprietary AI system prompts—from OpenEvidence’s AI platform, raising serious concerns about intellectual property and trade secret protections in AI development.
As Doximity integrates Pathway’s reference platform into its ecosystem, key questions arise: How will the acquisition affect clinician workflow efficiency and quality of care? Can the company navigate the legal challenges surrounding prompt injection ethically and responsibly? And will the combined capabilities solidify Doximity’s role as an indispensable AI partner to healthcare professionals?
Going forward, stakeholders will watch how Doximity leverages Pathway’s tools while ensuring legal clarity and maintaining trust in clinical AI applications—especially vital in a sector where accuracy and confidentiality materially impact patient outcomes.
